1,045 research outputs found
Cost effectiveness of aortic valve therapies: a systematic review of the literature
Background: we performed a systematic review on the cost effectiveness of transcatheter aortic valve implantation (TAVI) to standard aortic valve replacement and medical management in high-risk elderly patients with severe aortic stenosis.
Methods: in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses, a systematic review on current literature for cost-effectiveness of TAVI, standard aortic valve replacement, and medical management for elderly patients with high-risk severe aortic stenosis was performed. Incremental cost effectiveness ratio is used to measure effectiveness through life years gained or quality adjusted life years. Drummond checklist was used to further assess the quality of the included studies.
Results: the systematic literature search identified 4 primary publications (derived from 52 citations) that fulfilled the inclusion criteria. Tremendous discrepancy in incremental cost effectiveness ratio is demonstrated with operable patients similar to Cohort A of the PARTNER trial (€ 749 416 and € 39 577). Inoperable patients similar to Cohort B of the PARTNER trial suggest notable differences in favour for transcatheter aortic valve implantation with an increase in quality adjusted life years (0.06 versus 1.6, respectively). With lifetime horizon to transcatheter aortic valve implantation there is a more comparable incremental cost effectiveness ratio in the literature (€ 38 260 and € 37 432). Lowest incremental cost effectiveness ratio witnessed in the technical inoperable group at € 26 482. Lifetime horizon of 10 years with transcatheter aortic valve implantation differ (€ 39 388 versus € 19 947). Overall, a review of the literature suggests TAVI usage in patients for severe aortic stenosis whom are not eligible for surgery. All the studies were overall judged of medium-high quality.
Conclusions: transcatheter aortic valve replacement is more cost effective with a lifetime horizon for the treatment of patients with high-risk aortic stenosis compared with medical management considering those ineligible for standard aortic valve replacement. Further cost effectiveness research is needed in the stratifications of patient risk and patient co-morbidities for those candidates eligible for surgery.  
Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand
Objectives. Haemophilia A is a congenital disorder of coagulation that mainly affects males and causes a considerable use of
resources, especially when hemophilic patients are treated with prophylaxis. The aim of the present review was to discuss and
appraise the methodological aspects and results of published economic evaluations of haemophilia A treatments in the last
decade. Methods.The literature search, performed by consulting four engines, covered studies published between 2002 and 2014.
Full economic evaluations published in English language were identified and included in the review. A quality assessment of
the studies was also carried out based on Drummond’s checklist. Results. After careful evaluations of the identified records, 5
studies were reviewed. Primary and secondary prophylaxis resulted cost-effective compared to on-demand therapy: the ICER of
primary prophylaxis ranged from C40.236 to C59.315/QALY gained, while the ICER of secondary prophylaxis was C40.229/QALY
gained. Furthermore, 60% were high quality and 40% were medium quality studies. Conclusions.The review underlines the cost-effectiveness
of prophylaxis versus on-demand treatment and the different methodological approaches applied. Further economic
evaluations are required with models that reflect the clinical reality and consumption of resources in each countr
Moving towards compulsory vaccination: The Italian experience
Vaccine hesitancy is a phenomenon that has increased widely in the last few years, in the Europe and in the USA, giving its consequences on vaccine coverage rates. The decrease in those rates caused an enormous spread of preventable infections that were quite rare in the past years, or, at least, presented mild consequences. Since immunization is an issue of coverage rates, the European Council prompted the National Health Authorities to face the challenge of reaching the target of 95% of the population, set by European Centre for Disease Prevention and Control (ECDC), through the implementation of effective vaccination policies.
In Italy, coverage rates have been decreasing in the last few years. In 2016, the following coverage rates at 24 months for birth cohort 2014 have been reported by Italian..
Why we need to escape from our silos
Publisher Copyright: © 2024 John Wiley & Sons Ltd.The COVID-19 pandemic revealed major failings in many countries. We argue that one of the reasons, at global, national, and local levels, was that those involved were working in silos, unable to bring together the many diverse perspectives needed to respond to this complex problem. This is despite a growing recognition of the importance of adopting a Health For All Policies approach. Silo working, and the problems it creates, are not unique to health policy so there are opportunities to learn from those organisations that have tackled this issue.publishersversioninpres
- …